JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price objective on AstraZeneca (LON:AZN) in a research report report published on Tuesday, September 25th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Other equities analysts have also issued reports about the stock. Barclays restated an overweight rating and issued a GBX 6,600 ($86.24) price target (up from GBX 6,500 ($84.93)) on shares of AstraZeneca in a research report on Friday, August 10th. HSBC set a GBX 4,840 ($63.24) price target on shares of AstraZeneca and gave the company a sell rating in a research report on Wednesday, August 15th. Shore Capital restated a hold rating on shares of AstraZeneca in a research report on Wednesday, August 15th. Liberum Capital reiterated a hold rating on shares of AstraZeneca in a research report on Thursday, August 23rd. Finally, Jefferies Financial Group set a GBX 6,200 ($81.01) target price on shares of AstraZeneca and gave the stock a neutral rating in a research report on Thursday, August 16th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of GBX 5,700.70 ($74.49).
LON AZN traded down GBX 70 ($0.91) on Tuesday, reaching GBX 5,546 ($72.47). The company’s stock had a trading volume of 2,077,869 shares, compared to its average volume of 2,310,000. AstraZeneca has a 52 week low of GBX 4,260 ($55.66) and a 52 week high of GBX 5,520 ($72.13).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: Insider Trading – What You Need to Know
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.